Aytu Biopharma (AYTU) Invested Capital (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Invested Capital data on file, last reported at $45.6 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $45.6 million, up 23.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.6 million (up 23.94% YoY), and the FY2025 annual result was $20.8 million, down 29.59% from the prior year.
• Invested Capital grew to $45.6 million in Q1 2026 per AYTU's latest filing, from $16.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $77.0 million in Q1 2022 and troughed at $16.1 million in Q4 2025.
• A 5-year average of $42.5 million and a median of $38.0 million in 2025 frame the typical range for Invested Capital.
• On a YoY basis, Invested Capital climbed as much as 393.51% in 2022 and fell as far as 61.45% in 2022.
• A 5-year view of Invested Capital shows it stood at $60.8 million in 2022, then plunged by 44.29% to $33.9 million in 2023, then retreated by 3.71% to $32.6 million in 2024, then tumbled by 50.78% to $16.1 million in 2025, then soared by 183.68% to $45.6 million in 2026.
• Business Quant data shows AYTU's Invested Capital at $45.6 million in Q1 2026, $16.1 million in Q4 2025, and $38.0 million in Q3 2025.